These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women.
    Author: Bergquist C, Nillius SJ, Wide L.
    Journal: Contraception; 1980 Sep; 22(3):287-93. PubMed ID: 7002443.
    Abstract:
    The potent stimulatory luteinizing hormone-releasing hormone (LRH) analogue D-Ser(TBU)6-EA10-LRH was administered once daily during the luteal phase of the human menstrual cycle. The treatment was instituted in the early or mid-luteal phase of the cycle. Early luteal phase institution of intranasal treatment with 600 micrograms of the LRH agonist once daily reduced the basal progesterone levels during the luteal phase in 4 women but did not cause premature onset of menstruation. Mid-luteal phase institution of subcutaneous treatment with 10 micrograms of the LRH agonist once daily did not affect the progesterone levels or reduce the length of the luteal phase in 5 women. Thus, daily postovulatory administration of the LRH agonist D-Ser(TBU)6-EA10-LRH did not cause luteolysis in normally cycling women. Induction of luteolysis with superactive agonists of luteinizing hormone-releasing hormone (LRH) may provide an effective means of or prevention or interception of implantation. This study examines the effects of daily administration of superactive LRH agonist D-ser (TBU) 6-EA10-LRH during luteal phase of menstrual cycle of 8 healthy regularly menstruating women aged 24 to 32 (mean age, 29 years). 5 women were given daily administration of intranasal treatment with 600 ug of LRH agonist during the early luteal phase of the menstrual cycle. This treatment reduced the basal progesterone levels during the luteal phase in 4 women but did not cause premature onset of menstruation. 5 women self-administered 10 ug of LRH agonist subcutaneously once daily during the mid-luteal phase. This treatment did have any effect on the progesterone levels or length of luteal phase. There were no side effects during or after the treatment period. Daily postovulatory administration of the above LRH agonist did not cause luteolysis in normally cycling women. Further research should be done to determine if LRH agonists are effective as postovulatory contraceptive agents.
    [Abstract] [Full Text] [Related] [New Search]